Elevance Health, US0367521038

Elevance Health stock upgraded to Buy by Argus

Published on 11/19/2026 at 13:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health stock received a Buy upgrade after Argus lifted its rating from Hold. The analyst sees stronger EPS growth in 2027 as margin actions gain traction.

Analyst sees stronger earnings path

  • Argus upgraded Elevance Health from Hold to Buy.
  • The analyst expects stronger earnings-per-share growth in 2027.
  • Operating-margin actions are central to the improved outlook.
Elevance Health, US0367521038, Illustration mit AI erstellt.

Argus upgraded Elevance Health from Hold to Buy on Wednesday, November 18, according to Markets Insider. The analyst cited a path toward improved profitability and stronger earnings-per-share growth in 2027.

Argus sees room for earnings growth

The rating change puts greater emphasis on Elevance Health's operating-margin initiatives. Argus expects those actions to gain traction and support a stronger earnings profile next year.

For investors, the upgrade signals a more constructive view of the insurer's ability to improve profitability. The assessment focuses on the company's earnings trajectory rather than on a new company-issued forecast.

Elevance Health stock traded at 366.30 euros on Lang & Schwarz at 13:45 CET on Thursday, November 19.

Elevance Health at a glance

  • Company: Elevance Health
  • ISIN: US0367521038
  • Ticker: ELV
  • Lang & Schwarz quote: 366.30 euros on November 19, 2026, at 13:45 CET

The upgrade adds a positive analyst signal to the stock's recent focus on Medicaid profitability, medical-cost trends and the earnings base for 2027. The investment case remains tied to whether margin improvement translates into sustainable earnings growth.

The broader U.S. equity market is represented by the S&P 500.

More news and analyses on Elevance Health stock

Disclaimer...
en | US0367521038 | ELEVANCE HEALTH | boerse | 70536076 | bgmi